Ignite Creation Date:
2024-05-06 @ 3:03 PM
Last Modification Date:
2024-10-26 @ 1:42 PM
Study NCT ID:
NCT04507763
Status:
COMPLETED
Last Update Posted:
2021-10-28
First Post:
2020-07-27
Brief Title:
Study To Evaluate The Impact Of Early Initiation Of Biological Treatment With Ankylosing Spondylitis
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
Clinical Outcomes of Early Versus Delayed Management of Iraqi Patients With Ankylosing Spondylitis AS With Etanercept
Status:
COMPLETED
Status Verified Date:
2021-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is to evaluate available data in Iraqi patients with ankylosing spondylitis on Enbrel treatment with regards to the impact of early treatment using data from the Baghdad Teaching Hospital registry
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None